Abbott Laboratories

Equities

ABT

US0028241000

Medical Equipment, Supplies & Distribution

Market Closed - Nyse 04:00:02 2024-04-23 pm EDT 5-day change 1st Jan Change
107.6 USD +0.49% Intraday chart for Abbott Laboratories -1.48% -2.25%

This article is reserved for members

Already a member?

Log In

Not a member ?

Free registration
Daiwa Securities Trims Abbott Laboratories Price Target to $125 From $126 MT
Barclays Adjusts Abbott Laboratories' Price Target to $140 From $141, Maintains Overweight Rating MT
UBS Raises Abbott Laboratories Price Target to $143 from $136, Buy Rating Kept MT
Correction to Health Care Roundup Article DJ
RBC Lowers Price Target on Abbott Laboratories to $125 From $128, Keeps Outperform Rating MT
Raymond James Adjusts Abbott Laboratories' Price Target to $124 From $127, Keeps Outperform Rating MT
Health Care Down After Abbott Earnings -- Health Care Roundup DJ
Sector Update: Health Care Stocks Retreating Late Afternoon MT
News Highlights : Top Company News of the Day - Wednesday at 3 PM ET DJ
S&P 500, Nasdaq dip as interest rate concerns, earnings weigh RE
Abbott Laboratories Raises Midpoint of 2024 Guidance After First-Quarter Beat MT
Top Stories at Midday: U.S. Bancorp, Abbott, Citizens Financial, First Horizon, Prologis, ASML, Travelers Report Earnings; Tesla Asks Shareholders Vote on Musk's Compensation; Eli Lilly Sleep Apnea Drug Trials Hit Primary Endpoints MT
News Highlights : Top Company News of the Day - Wednesday at 1 PM ET DJ
News Highlights : Top Company News of the Day - Wednesday at 11 AM ET DJ
Wall St slips as dour earnings, chip stocks weigh RE
Sector Update: Health Care Stocks Advance Premarket Wednesday MT
News Highlights : Top Company News of the Day - Wednesday at 9 AM ET DJ
Transcript : Abbott Laboratories, Q1 2024 Earnings Call, Apr 17, 2024
Abbott: target ranges for 2024 tightened upwards CF
Abbott Laboratories' Q1 Adjusted Earnings Down, Revenue Up; 2024 Outlook Narrowed MT
Earnings Flash (ABT) ABBOTT Posts Q1 Revenue $9.96B, vs. Street Est of $9.87B MT
Earnings Flash (ABT) ABBOTT Posts Q1 EPS $0.98, vs. Street Est of $0.95 MT
Abbott Laboratories Reports Earnings Results for the First Quarter Ended March 31, 2024 CI
Abbott Laboratories Provides Earnings Guidance for the Second Quarter and Full Year of 2024 CI
Abbott beats quarterly profit estimates on strong medical device sales RE
Chart Abbott Laboratories
More charts
Abbott Laboratories specializes in the research, development, manufacturing and marketing of pharmaceutical and medical products. Net sales break down by family of products as follows: - diagnostic systems and instruments (39.1%); - vascular devices (24.7%): endoprosthetic systems, dilation catheters, arterial closures, etc.; - nutrition products (12.1%): pediatric nutrition products, nutritional supplements, and dietetic products; - medicine (8.2%): anesthetics, antiviral products, antibiotics, inhibitors, anti-inflammatories, etc.; - other (15.9%). Net sales are distributed geographically as follows: the United States (38.5%), Germany (5.8%), China (5.6%), India (4.4%), Switzerland (4.1%), Japan (3.8%), Netherlands (2.7%) and others (35.1%).
Calendar
Related indices
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
C+
More Ratings
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
25
Last Close Price
107.6 USD
Average target price
126.3 USD
Spread / Average Target
+17.42%
Consensus
  1. Stock Market
  2. Equities
  3. ABT Stock
  4. News Abbott Laboratories
  5. Abbott Laboratories Maintains Quarterly Dividend at $0.55 a Share, Payable May 15 to Holders of Record April 15.